$INO “We do not need the hold on Cellectra lifted by the FDA to start our trial. We have been in talks with our target countries and are trying to get the trial started ASAP. As it is the first time we are working on some of these countries, it has been a learning experience for us as well. We had underestimated the time required. The Advaccine IPO, while delayed, should be approved. They are using top bankers and our science is sound and holds a tremendous promise. The trial delay is not related to Advaccine’s IPO delay.” 7/15/21